All In Biotech

Drug Trial Radar · NCT05871541

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

A Phase 1 Randomized, Double-Blinded, Active-Controlled, 2-Dose Study to Assess the Safety and Immunogenicity of a Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects 50 to 69 Years of Age.

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

May 26, 2023

Primary completion

Mar 25, 2024

Study completion Mar 25, 2024

Sponsor

Lead sponsor
Immorna Biotherapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
ICON plc
First posted
May 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 69 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the safety and immunogenicity of a self-replicating (sr) RNA-based vaccine, JCXH-105, in the prevention of Shingles (Herpes Zoster) Participant will be randomized to receive either JCXH-105 or Shingrix.

Conditions

  • Herpes Zoster (HZ)
  • Shingles
  • Infectious Disease

Interventions

  • JCXH-105Biological

    As IM injection

  • Active Control (Shingrix)Biological

    As IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAE FrequencyTime frame: Day 1 - Day 241
  2. Injection site reactionTime frame: 7 days after the first and second vaccination
  3. Solicited systemic reaction frequencyTime frame: 7 days after the first and second vaccination
  4. AE frequencyTime frame: 30 days after the first and second vaccination
  5. Medically attended AE frequencyTime frame: Day 1 - Day 241
  6. The frequency of potential immune-mediated adverse events"Time frame: Day 1 - Day 241

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • CenExel RCA

    Hollywood, Florida

  • CenExel FCR

    Tampa, Florida

  • CenExel HRI

    Berlin, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.